Adverse effects analysis results during anti-TB treatment among hemodialysis patients

<b>Introduction:</b> The presence of active tuberculosis (TB), post TB changes or latent TB infection among hemodialysis (HD) patients require anti-TB treatment. It added complexity for most of doctor. Aim. To provide an analysis for adverse effects (AE) among HD patients during anti-TB treatment. <b>Materials and methods:</b> We studied 42 HD patients (f. - 54.8%, m. 45.2%, age - 39.45 years): with active TB - 73.8%, with residual post-TB changes - 26.2%. <b>Results:</b> Active TB identified in 77.4% cases: the sensitivity preserved in 31.8%, H- resist. - 18.2%, MDR - 45.5%, XDR - 4.5%. Due to contraindications taken place standard regimens were not applicable. There were introduced 24 schemes of anti-TB therapy. Anti-TB therapy was selected in 92.9%. During anti-TB treatment an increase of uremia - 20.5%, cardiovascular complications - 17.9%, neurotoxic reactions - 15.4%, toxic-allergic reactions - 10.3%, articular syndrome - 5.1%, cardiac conduction disorders - 5.1%, indomitable vomiting and hematotoxic reactions - 2.6%. Most often canceled anti-TB drugs: H - 12.8%, Z - 12.8%, R - 10.3%, Et - 10.3%, PAS - 5.1%, one patient per each drug reported improvement after withdrawal Lfx, Am, Cs, Pt. <b>Conclusion:</b> Patients with drug-resistant TB predominate - 68.2%. During HD patients TB treatment standard regimens are not applicable, the treatment duration exceeds 6 months. In 92.9% of HD patients, it is possible to select anti-TB therapy. Among the AE of anti-TB drugs, there is more often an increase of uremia - 20.5%, cardiovascular complications - 17.9%. The drugs requiring withdrawal were often H - 12.8%, Z - 12.8%.